BioNTech SE Chief Financial Officer Ramon Zapata Gomez received new equity-based compensation. He was granted 15,103 Performance Share Units and 18,879 options, each tied to one ordinary share. The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash.
Both the PSUs and options vest annually in equal installments over four years starting on the first anniversary of the grant. They become exercisable four years after the grant date and are subject to performance and other conditions, including share-price targets relative to the Nasdaq Biotechnology Index.
BioNTech SE reported new equity awards to officer Ryan James Timothy Patrick. On May 12, 2026, he received 10,069 Performance Share Units and an option over 12,586 ordinary shares as compensation, both at a grant price of zero.
The option carries an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the PSUs and options vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions. PSU performance targets are based on BioNTech’s share price relative to the Nasdaq Biotechnology Index.
BioNTech SE Chief Operating Officer Sierk Poetting reported compensation-related equity grants. He received 10,069 Performance Share Units and 12,586 options, each linked to ordinary shares. These awards were granted at no cash cost to him and are classified as derivative securities.
The options carry an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to specified performance and service conditions.
BioNTech SE reported that Chief People Officer Kylie Jimenez received new equity-based compensation. She was granted 8,391 performance share units, each economically equivalent to one ordinary share, and options over 10,488 ordinary shares.
The performance share units and options both vest annually in equal installments over four years starting on the first anniversary of the grant date and become exercisable four years after the grant date, subject to performance-based and other conditions. The option has an exercise price of EUR 89.38 and may be settled in ordinary shares, ADSs, and/or cash at the supervisory board’s election.
BioNTech SE Chief Commercial Officer Annemarie Hanekamp received new equity-based compensation awards. She was granted 10,069 performance share units and options on 12,586 ordinary shares, both with no upfront purchase price. The options have an exercise price of EUR 89.38 and may be settled in shares, ADSs, or cash at the supervisory board’s election. Both the options and PSUs vest in equal annual installments over four years starting on the first anniversary of the grant date and become exercisable four years after grant, subject to performance and service conditions.
BioNTech SE submitted a Form 144 notice relating to the proposed sale of American Depositary Shares representing ordinary shares and ordinary shares, no par value. The filing lists stock option exercise dates of 11/21/2022 and 08/09/2024 and references 05/13/2026 and Nasdaq Global Select.
BioNTech SE has authorized a new share repurchase program allowing the company to buy back American Depositary Shares for an aggregate amount of up to $1.0 billion. The program runs until and including May 6, 2027 and will be funded from existing cash resources.
The repurchased ADSs are expected to be used to satisfy obligations in the ordinary course of business. BioNTech describes the program as supporting capital efficiency, long-term value creation and financial flexibility as it pursues its objective to become a multi-product company by 2030.
BioNTech reported a much weaker first quarter of 2026 as COVID-19 revenues continued to decline and investment in its oncology pipeline accelerated. Revenues fell to €118.1 million from €182.8 million a year earlier, mainly because COVID‑19 vaccine revenues dropped to €66.9 million from €133.0 million.
Heavy spending on R&D of €557.0 million, plus higher sales and marketing and general and administrative costs, led to an operating loss of €677.5 million and a net loss of €531.9 million, or €2.10 per share, compared with a €1.73 loss per share last year.
Despite the loss, BioNTech’s balance sheet remained strong, with €9,939.4 million in cash and cash equivalents and total cash, cash equivalents and security investments of €16,763.3 million as of March 31, 2026. The company plans to launch a share repurchase program of up to $1.0 billion of ADSs over the next twelve months.
BioNTech also announced a major manufacturing footprint consolidation, planning to exit operations at sites in Idar‑Oberstein, Marburg, Singapore and CureVac locations, plus wind down subsidiary JPT Peptide Technologies. These measures could affect about 2,000 positions in total and are intended to generate recurring annual cost savings by 2029 while supporting the shift toward a broader late‑stage oncology portfolio.
BioNTech SE reported a weak but strategy-heavy first quarter of 2026, as COVID-19 vaccine demand declined while oncology investments accelerated. Revenues fell to €118.1 million from €182.8 million a year earlier, driven mainly by lower COVID-19 vaccine sales. The company posted a net loss of €531.9 million (adjusted net loss €494.6 million), with diluted loss per share of €2.10 (adjusted €1.95), compared with a €415.8 million loss and €1.73 per share in 2025.
BioNTech reaffirmed its 2026 guidance, including total revenues of €2.0–2.3 billion, adjusted R&D of €2.2–2.5 billion and adjusted SG&A of €700–800 million, underscoring its continued pivot from COVID-19 to oncology. R&D spending rose to €557.0 million, largely for immuno‑oncology and antibody‑drug conjugate programs such as pumitamig and gotistobart, and for integrating the BioNTech China and CureVac acquisitions.
Liquidity remained strong, with €16.8 billion in cash, cash equivalents and security investments as of March 31, 2026, and 252,884,261 shares outstanding (excluding treasury shares. Management and the Supervisory Board expect to authorize a share repurchase program of up to $1.0 billion over twelve months. BioNTech also plans to consolidate its manufacturing footprint, exiting sites in Idar‑Oberstein, Marburg, Singapore and CureVac locations, affecting up to approximately 1,860 positions and potentially yielding about €500 million in recurring annual savings by 2029 to support oncology development.
BioNTech SE Chief Operating Officer Sierk Poetting reported an indirect open-market sale of 50,000 Ordinary Shares. The shares were sold at an average price of $110.5592 per share and are held through Tofino GmbH, a company of which Poetting is the sole shareholder.
After this transaction, indirect holdings reported for Poetting through Tofino GmbH total 399,387 Ordinary Shares. This filing reflects a net sale, with no option exercises or derivative transactions disclosed in this report.